Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
72 hedge funds and large institutions have $691M invested in Intercept Pharmaceuticals, Inc. in 2013 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 28 increasing their positions, 15 reducing their positions, and 7 closing their positions.
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
87% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 15
73% more capital invested
Capital invested by funds: $399M → $691M (+$291M)
26% more funds holding
Funds holding: 57 → 72 (+15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$23.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.2M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$7.88M |
| 4 |
Millennium Management
New York
|
+$7.33M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$5.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$6.42M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$6.27M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$4.94M |
| 4 |
JP Morgan Chase
New York
|
-$4.76M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.63M |
ICPT Hedge Fund Activity: Q3 2013 in Review
72 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2013, worth a combined $691M — up 73% from $399M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ICPT positions and 7 closed out — a net gain of 15 holders — while 28 added to existing stakes and 15 trimmed.
The largest buyer was SAC Capital Advisors, adding an estimated $23.5M. The largest seller was Capital World Investors, cutting an estimated $6.42M.
- 72 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2013, up from 57 in Q2 2013.
- Funds reported $691M of Intercept Pharmaceuticals, Inc. stock for Q3 2013, up 73% quarter-over-quarter.
- 22 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2013 and 7 closed out, a net change of +15 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2013 was SAC Capital Advisors, an estimated $23.5M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q3 2013 was Capital World Investors, an estimated $6.42M sold.
Based on aggregated 13F filings for Q3 2013.